GSK hits trouble with Trelegy as EU regulators block asthma ...

European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of fl

Vaccine sales recover at GSK in Q3, but lockdown fears weigh...

GlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the second as a result of the COVID-19 pandemic, putting it back on course to meet the lower end

Novartis on point in EU for asthma triple as CHMP backs Ener...

Shingrix and Trelegy shield GSK from Advair fallout

Trial could unlock asthma use for GSK’s Trelegy

GlaxoSmithKline CEO Emma Walmsley has been predicting big things for respiratory triple therapy Trelegy in the next couple of years and has new data that could open up a new market.